Who Produces Eureka Kits
What you are about to read is a quick representation of Eureka Lab Division and what it did to succeed in researching, developing and producing
the World ‘s Largest Range of Diagnostic Kits
for chromatographic analytical instruments
Many years ago, Dr. Gilberto Coppa and Dr. Stefano Sartori decided to pursue a professional path that few companies had dealt with:
the analytical procedures existing in clinical laboratories, thanks to the realization of
using HPLC, GC, GC-MS, LC-MS / MS chromatographic techniques.
From the very outset, they concentrated their activity on the development of an Analytical Method for the Determination of Urinary and Plasma Catecholamines in HPLC with Fluorimetric Revelation.
The decision to work with Catecholamine was due to the shared thought, along with many Oncologists, that the need of Formulating a Correct Diagnosis of cancer patients was fundamental and extremely important
The concentration of catecholamines (Noradrenaline, Adrenaline, Dopamine), which are a group of hormones produced by the adrenal gland, are greatly increased in biological fluids in the presence of such pathologies.
To help doctors to properly diagnose these tumor forms, they asked some laboratories about their problems and issues in their structures since the 1970s.
Here are some of the problems raised:
Direct measurement in amperometry was sufficiently sensitive for the analysis of noradrenaline and urinary dopamine, but it was not sufficiently sensitive for the quantitative analysis of urinary adrenaline.
Direct measurement in amperometry was not sufficiently sensitive for the analysis of plasma catecholamines even when starting from a high plasma volume (at least 2 ml).
Direct measurement in amperometry had taken the role of reference technique for a long time, but the amperometric detector proved to be difficult to handle for routine analysis.
Despite the replacement of the amperometer detector with the, more sensitive Coulometric detector, it was still difficult to handle for routine analysis as well as being particularly costly.
After collecting this information relative to the problems arising from the use of the amperometer and coulometric detector they decided to “create”
Our team worked long for the development of a fluorimetric, chromatographic, analytical method for the determination of catecholamines with the benefit that:
International research from the ’90s was geared towards selecting more powerful analytical methods capable of selectively analyzing catecholamines in biological fluids, compared to methods born at the end of the 1970’s in ammeters.
Works published by the Japanese groups of Y. Ohkura, K. Imai, H. Iizuka, M. Yamaguchi and by the Dutch G. Alberts and F. Boomsma, led to the selection of a selective quantitative yield reagent for the catecholic group that was transformed to a benzotriazole group, with a FLUORESCENCE response of 50 times higher than the amperometric detection.
Their work involved the development of a biologic matrix purification method that was more self-explanatory than the methods used up to that time.
After purification, the sample undergoes a process of derivatization.
At this point, the derivatized sample is read in fluorimetry, allowing it to obtain excellent sensitivity and specificity for the analysis.
This has allowed us to reach the much anticipated goal:
the analytical procedures existing in clinical laboratories regarding the dosage of both urine and plasma catecholamines.
But this was just the beginning … Since 2000 the Eureka Lab Division Team, has continued to develop
Initially the Team dealt with
Liquid Chromatography (HPLC / UHPLC) coupled to
(for analysis of SPECIAL CLINICAL CHEMISTRY, CLINICAL PHARMACOLOGY and OCCUPATIONAL TOSSICOLOGY)
We then dedicated ourselves to
Gas Chromatography (GC) coupled to detectors:
FID (flame ionization detector)
ECD (electron capture detector)
(for analysis of SPECIAL CLINICAL CHEMISTRY, OCCUPATIONAL TOXICOLOGY AND FORENSIC TOXICOLOGY)
Finally, since 2008, we have focused our work on
Liquid Chromatography (LC) coupled with
Mass Spectrometer / Triple Quadruple
(for analysis of SPECIAL CLINICAL CHEMISTRY, CLINICAL PHARMACOLOGY AND FORENSIC TOXICOLOGY)
In order to be able to continuously increase the production of new Eureka Kits, the company has for several years been working with the
“STUDY GROUP OF EXTERNAL AUTHORS”
They are Specialists in Clinical Biochemistry, Pharmaco – Toxicology and expert in
Chromatographic Analytical Techniques.
They collect the requests of Doctors who are in close contact with patients and iniziate for the development of Chromatographic Analytical Methods that will then be engineered into EUREKA KITS.
It’s like having many research and development teams across Italy working to increase the development of new chromatographic analytical methods that will then be engineered in the form of ready-to-use kits.
After long research and development work by Eureka Lab Division Team and by the Study Group of Foreign Authors, Eureka Kit is Validated to GUARANTEE their
This work is done by the
“STUDY GROUP OF EXTERNAL VALIDATORS”
They are also passionate about chromatographic analytical techniques and make available their analytical systems and their human biological samples.
It is crucial to have the opportunity to use more chromatographic analytical systems and human biological samples , because ONLY THEN is it possible to determine
THE KIT’S STRENGTH
EASY OF USE
That is why thanks to the work of Eureka Team, together with the group of “Authors and Validators” , we can
to Clinical Laboratories around the World
that the Eureka Kits
WORK CORRECTLY AND PROVIDE APPROPRIATE RESULTS
To confirm the correct operation and the appropriate results of the Eureka Kits, we have been participating in Quality Control Programs (VEQs) for several years,
SPECIAL CLINICAL CHEMISTRY INSTAD
CLINICAL PHARMACOLOGY INSTAD
OCCUPATIONAL TOXICOLOGY G-EQUAS
FOREST TOXICOLOGY IST. SUP. DI SANITA ‘
Visit www.eurekaone.com and check out our results